1 Platform, 4 Therapies: What "Configurable" Really Means
How does a patient access program built for one therapy become a program that works for the next one, without starting from zero?
Every Market Access lead who has launched a patient support program knows the pattern. The first program takes months to build. Then a second therapy is added, and the build starts over: new eligibility rules, new funding flows, new hospital onboarding, new reporting.
In emerging markets, that rebuild cost is a barrier to access in its own right. Across ASEAN, out-of-pocket spending still averages roughly 31% of total health expenditure. Each therapy that waits for its own custom program is a group of patients waiting for support.
"Configurable" is the word vendors use to answer this. It usually means very little. Here is what it means in practice.
Multi-therapy areas One engine
Medaccess platform supports access programs across many therapy areas:
Oncology
Rare disease, including cardiac and ophthalmic conditions
Vaccines
These areas differ in patient journey, cost structure, care setting and sponsor needs. An oncology patient may need sustained, multi-cycle subsidy support. A rare disease co-payment program is a different shape of problem. The platform underneath them is the same.
What "configurable" really means
A configurable platform separates what stays fixed from what changes per program.
The fixed core is the same in every program:
Digital affordability screening (with optional Instant Means testing)
Patient consent and data-privacy architecture
A timestamped audit trail on every decision
Hospital connectivity and a patient-support call center with CRM
Provider network: hospitals, clinics and pharmacies, public and private, onboarded per program
The configuration layer changes per program:
Eligibility rules: who qualifies, and on what criteria
Funding model: multi-discount with hospitals, distributor-run daily operations, microfinancing, free-of-charge supply, or a copayment structure
Transparent sponsor fund flow, with near real-time settlement to the point of care
A new program means setting up the configuration layer, not rebuilding the core. In MED's model, a program build typically takes about six weeks of pure development, with pre-development and post-development phases around it.
The funding model is a choice made for each program, not a constraint of the platform. Most vendors build one model that fits all and call it a platform.
The fund flow layer: where most co-payment programs stall
Eligibility is only half of a copayment program. The other half is moving the money: from sponsor funding to the hospital, clinic or pharmacy, with every payment traceable to a decision. Across three countries with three currencies, three banking systems and different foreign-exchange rules, this is often where programs slow down. Cross-border transfers get batched, delayed and eroded by transaction fees.
Medaccess runs program fund flow through a strategic entity in Singapore, which acts as a single regional funding point for sponsors. For copayment and rebate programs, this makes possible:
Near real-time processing. Once an eligibility decision is made, each transaction is processed almost instantly in batches.
Full-value payout. Local hospitals, clinics and pharmacies receive the net approved amount, with no additional bank fees deducted.
One funding point and one audit trail, from the sponsor's contribution to the final payout
For a sponsor, this means more of the program budget reaches the point of care rather than the banking chain, and finance and compliance teams can see where every payment went.
Scale: where configurability has been tested
A model is only configurable if it holds up in more than one setting. EasyGop runs nationwide across Vietnam, the Philippines and Indonesia, three health systems with different payer mixes, regulations and provider landscapes.
Scale matters here for a practical reason. Providers already connected to the platform can be offered new programs without a new integration. Patient-level data gathered across programs improves how eligibility is assessed. Each new therapy added to a platform with proven coverage starts from a stronger position than the one before it.
Why this matters for a scalable launch plan
Market-specific financing realities mean no single program design fits every market or therapy.
For a Market Access team planning a portfolio rather than a single launch, this changes the question from "can we build a program for this product?" to "how quickly can we extend the one that already works?"
EasyGop lets each program be configured to its market and therapy, and our Singapore strategic entity moves program funds in near real time, from eligibility screening through to audited payout, without starting over each time.
If your team is planning access across more than one therapy or more than one market, we'd welcome the conversation. Get in touch with MED to see what a configured program could look like for your portfolio.